Exchange: NYSE·Updated 07:30 PM EST
ZBH logo

ZBH Zimmer Biomet Holdings Inc

$100.82
$0.37
(0.36%)
Today
Closed $101.10
$0.28
(0.28%)
After Hours
Reported EarningsNov 4
Mkt Cap$19.13B
Vol2.96M

About ZBH

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
49

Neutral Sentiment

How do you feel about ZBH?

topstockalerts
Wells Fargo upgraded Zimmer Biomet Holdings to Overweight and established a $123 price target, citing improving growth prospects ahead of the launch of its Monogram robotic surgical system. Analyst Larry Biegelsen said Monogram addresses the main weakness in the company’s otherwise mid-single-digit growth portfolio: its knee business, which accounts for approximately 38% of sales and is expected to decline slightly in 2026. The upcoming robotic system could help reverse that weakness by improving surgical precision and patient outcomes. Stifel also raised its price target to $140 from $125 while reiterating a Buy rating, following positive feedback from high-volume orthopedic surgeons at a healthcare conference. Physicians highlighted Monogram’s potential to reduce surgeons’ physical workload through automated bone cutting while improving procedural outcomes. Truist Securities likewise increased its target to $114. $ZBH
shoc24
$ZBH reported earnings before the open today. Adjusted EPS beat estimates: $1.90 vs. $1.88 expected, according to Stock Meadow.
StocktwitsEarnings
$ZBH Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $1.90 • Reported revenue of $2.06B up 3.07% YoY • Zimmer Biomet updated full-year 2026 guidance to reported revenue change of 4.4%-4.9%, constant-currency revenue change of 4.1%-4.6%, organic constant-currency revenue change of 3.0%-3.5%, and adjusted diluted EPS of $8.50-$8.60.

Advertisement|Remove ads.